CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus

Department of Internal Medicine-Infectious Diseases, Department of Gastroenterology and Hepatology, Department of Biostatistics, Department of Virology, rasmus MC University Medical Center, Rotterdam, The Netherlands; Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, Amsterdam, The Netherlands; ‡‡ *Department of Internal Medicine-Infectious Diseases, University Medical Center, Utrecht, The Netherlands; Department of Internal Medicine, Rijnstate Hospital, rnhem, The Netherlands; Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands

[1]  T. Berg,et al.  Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues , 2010, Hepatology.

[2]  Richard D Moore,et al.  Renal function with use of a tenofovir-containing initial antiretroviral regimen , 2009, AIDS.

[3]  J. Phair,et al.  Hepatitis B and long-term HIV outcomes in coinfected HAART recipients , 2009, AIDS.

[4]  Huy A. Nguyen,et al.  Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil , 2009, Hepatology.

[5]  A. Hatzakis,et al.  Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[7]  O. Kirk,et al.  HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies , 2008, AIDS.

[8]  J. Gallant,et al.  The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients , 2008, AIDS.

[9]  S. Lewin,et al.  A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand , 2008, Hepatology.

[10]  M. Buti,et al.  TWO YEAR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AND ADEFOVIR DIPIVOXIL (ADV) SWITCH DATA IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102), PRELIMINARY ANALYSIS , 2008 .

[11]  A. Lok,et al.  Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. , 2008, Journal of hepatology.

[12]  G. Vernet,et al.  Comparison of Reverse Hybridization, Microarray, and Sequence Analysis for Genotyping Hepatitis B Virus , 2008, Journal of Clinical Microbiology.

[13]  P. Lampertico,et al.  Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. , 2007, Gastroenterology.

[14]  B. Gazzard,et al.  The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years , 2007, AIDS.

[15]  O. Kirk,et al.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. , 2006, Archives of internal medicine.

[16]  T. Berg,et al.  Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy , 2006, Hepatology.

[17]  Michael D. Miller,et al.  Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus , 2006, Antimicrobial Agents and Chemotherapy.

[18]  C. Katlama,et al.  Anti‐hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV‐infected patients , 2006, Hepatology.

[19]  F. Tacke,et al.  Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.

[20]  A. Valleron,et al.  Long-term hepatitis B virus dynamics in HIV–hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate , 2005, AIDS.

[21]  Richard D Moore,et al.  Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. Mocroft,et al.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort , 2005, AIDS.

[23]  T. Berg,et al.  Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection , 2004, Hepatology.

[24]  B. Gazzard,et al.  Renal Dysfunction With Tenofovir Disoproxil Fumarate-Containing Highly Active Antiretroviral Therapy Regimens Is Not Observed More Frequently: A Cohort and Case-Control Study , 2004, Journal of acquired immune deficiency syndromes.

[25]  M. Bernardi,et al.  High risk of hepatocellular carcinoma in anti‐HBe positive liver cirrhosis patients developing lamivudine resistance , 2004, Journal of viral hepatitis.

[26]  E. Schiff,et al.  Durability of serologic response after lamivudine treatment of chronic hepatitis B , 2003, Hepatology.

[27]  B. Gazzard,et al.  An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals , 2003, AIDS.

[28]  M. Perazella,et al.  Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. , 2002, The American journal of the medical sciences.

[29]  H. Niesters,et al.  Detection of HBV DNA using real time analysis. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[30]  H. Lee,et al.  Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea , 2000, Hepatology.

[31]  R. D. de Man,et al.  Development of a Quantitative Real-Time Detection Assay for Hepatitis B Virus DNA and Comparison with Two Commercial Assays , 2000, Journal of Clinical Microbiology.

[32]  D. Cooper,et al.  The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. , 1991, The Journal of infectious diseases.

[33]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[34]  T. Berg,et al.  76 TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN SUBJECTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL (ADV) , 2008 .

[35]  T. Cihlar,et al.  NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 641–648 (2001) HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGS , 2003 .